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ABSTRACT
Neuronal atrophy is a common pathological feature
occurred in aging and neurodegenerative diseases. A
variety of abnormalities including motor protein mal-
function and mitochondrial dysfunction contribute to the
loss of neuronal architecture; however, less is known
about the intracellular signaling pathways that can pro-
tect against or delay this pathogenic process. Here, we
show that the DYNC1I1 deﬁciency, a neuron-speciﬁc
dynein intermediate chain, causes neuronal atrophy in
primary hippocampal neurons. With this cellular model,
we are able to ﬁnd that activation of RAS-RAF-MEK
signaling protects against neuronal atrophy induced by
DYNC1I1 deﬁciency, which relies on MEK-dependent
autophagy in neuron. Moreover, we further reveal that
BRAF also protects against neuronal atrophy induced
by mitochondrial impairment. These ﬁndings demon-
strate protective roles of the RAS-RAF-MEK axis against
neuronal atrophy, and imply a new therapeutic target for
clinical intervention.
KEYWORDS RAS-RAF-MEK pathway, atrophy, dynein
intermediate chain, mitochondria, hippocampal neuron,
autophagy
INTRODUCTION
For normal aging, age-related brain atrophy is a mild process,
responsible for increased risk of memory decline with increasing
age (Pakkenberg et al., 2003; Fox and Schott, 2004), whereas
the highly accelerated rate of brain atrophy has a major or sole
role in neurodegenerative diseases (Regeur et al., 1994; Schott
et al., 2003). Loss of neuronal architecture is the main contrib-
utor to brain atrophy (Swaab et al., 1994; Freeman et al., 2008),
thus atrophy of brain and neuron can be well deﬁned as the
shortening or shrinkage of neurites. Neuritic atrophy is a com-
mon pathological feature of many neurodegenerative disorders
including amyotrophic lateral sclerosis (ALS), Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD), and Huntington’s disease
(HD). A neuron consists of a soma and long neurites including
one axon andmultiple dendrites. The physiological structures of
neurons render them particularly vulnerable to motor protein
malfunction, protein aggregation, and mitochondrial dysfunc-
tion. Particularly, abnormalities to dynein and mitochondria are
linked to ALS (Soo et al., 2011).
Cytoplasmic dynein is the main driving force for minus-
end-directed transport of cargos (Holzbaur and Vallee,
1994). Cytoplasmic dynein is a large protein complex (∼1.5
MDa) containing heavy chains, intermediate chains, light
intermediate chains, and light chains (Pﬁster et al., 2005).
Mutations and 9-bp deletion of cytoplasmic dynein heavy
chain (Dync1h1) are sufﬁcient to cause neuron degeneration
(Hafezparast et al., 2003; Chen et al., 2007; Banks and
Fisher, 2008; Lipka et al., 2013). Mutations of cytoplasmic
dynein light intermediate chain 2 (Dync1li2) and dynein
intermediate chain (Dync1i) result in reduction of dendrite
arborization of Drosophila neurons (Zheng et al., 2008;
Boylan and Hays, 2002). However, less is known about the
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physiologic role of Dync1i in higher animals, especially the
isoforms of Dync1i1, which are neuron-speciﬁc and not
expressed in glia in the brain (Myers et al., 2007). Two genes
(Dync1i1 and Dync1i2) in rodents encode cytoplasmic
dynein intermediate chains, in which Dync1i1 is a neuron-
speciﬁc gene (Fig. 1A). In line with previous reports (Myers
et al., 2007), most mRNAs of the intermediate chain isoforms
are expressed in rat brain, while the mRNA of Dync1i2C and
Dync1i2B are expressed in most tissues (Fig. 1A). Here, we
demonstrate that the knockdown of Dync1i1 causes neu-
ronal atrophy and decreases mitochondrial motility in rat
primary hippocampal neurons.
Using the cellular model of neuronal atrophy caused by
DYNC1I1 deﬁciency, we are able to identify that RAS-RAF-
MEK signaling, but not PI3K-AKTsignaling, protects neurons
against dendritic atrophy in primary hippocampal neurons,
and reveals that RAS-RAF signaling activates MEK-depen-
dent protective autophagy. Moreover, we further demon-
strate that BRAF can also protect dendrites from atrophy
arisen from mitochondrial dysfunction. These ﬁndings of the
RAS-RAF-MEK pathway for neuronal atrophy protection
may provide a therapeutic target against the on-sets of
neuronal atrophy.
RESULTS
Knockdown of DYNC1I1 expression causes dendritic
atrophy of primary hippocampal neurons
Considering DYNC1I2 may play housekeeping function
(Myers et al., 2007) and neurites of cultured neuron grow fast
before 7 days in vitro (DIV7) (Dotti et al., 1988), we selec-
tively knockdown DYNC1I1 expression at DIV6 in rat primary
hippocampal neurons. Neurons transfected with shRNA1-6,
a speciﬁc shRNA of Dync1i1 (Fig. S1A–F), show reduced
dendritic complexity and shortened dendritic length (Fig. 1B–
D) compared to control neurons (Fig. 1E–G) at DIV11. For
dendritic branches, the length of single branch seldom dis-
tributes beyond 350 μm in control neurons or 200 μm in
DYNC1I1-knockdown neurons (Fig. 1H). Compared to the
total dendritic lengths of control neurons (1100 ± 453 μm, n =
75, mean ± SD), the total dendritic lengths of DYNC1I1
knockdown neurons (303 ± 307 μm, n = 101, mean ± SD)
are dramatically decreased (P < 0.001, t test) at DIV11
(Fig. 1I). Knockdown-resistant isoforms of Dync1i1 can
partially rescue the phenotype caused by shRNA1-6
(Fig. S1C–H). The data suggest that the functions of
DYNC1I1 in neuron are nonredundant and necessary for the
maintenance of neuronal architecture.
The potential effects of shRNA1-6 on dendritic develop-
ment or dendritic atrophy can both explain the reduced total
dendritic lengths of DYNC1I1 knockdown neurons. To
determine the effect of shRNA1-6, we have checked and
quantiﬁed total dendritic lengths at different time points (1, 3,
and 5 days) after shRNA1-6 transfection. As shown in
Fig. 1F, the distributions of total dendritic lengths show large
variance. For 1, 3, and 5 days after transfection, the total
dendritic lengths (in μm, mean ± SD) of control neurons are
1075 ± 330, 1130 ± 391, and 1307 ± 420, respectively; for
control shRNA1-4 transfected neurons, the lengths are 1037
± 230, 1010 ± 234, and 1006 ± 310; while the lengths of
shRNA1-6 transfected neurons are 1041 ± 340, 535 ± 119,
and 279 ± 113, respectively. These results are in line with
reports that the dendritic architecture of neurons are mature
at stage 4 (DIV4-7), while the maturation of synapses pro-
ceeds for following 2 weeks (stage 5) in vitro (Lalli, 2014).
The data demonstrate that the DYNC1I1 knockdown by
shRNA1-6 results in dendritic atrophy rather than dendritic-
development retardation (Fig. 1F). Thus, to address the
question of whether there is an intrinsic signaling pathway for
protecting neuron from atrophy, dendritic atrophy caused by
DYNC1I1 knockdown in primary hippocampal neuron is a
good cellular model of neuronal atrophy arisen by motor
protein dynein malfunction.
cFigure 1. Knockdown of cytoplasmic dynein 1 inter-
mediate chain 1 (Dync1i1) causes dendritic atrophy in
primary hippocampal neurons. (A) The quantitative-
PCR results show the expression levels of cytoplasmic
dynein 1 intermediate chains, including the isoforms of
Dync1i1 (1A, 1B, 1C, and 1D) and the isoforms of Dync1i2
(2A, 2B, and 2C) in P0 rat hippocampus, cortex, heart,
kidney, liver, and lung tissues. (B–G) Representative
neurons are transfected with shRNA1-6 (B–D, a speciﬁc
shRNA of Dync1i1, see also Fig. S1) or Ctrl (E–G) at DIV6
and immunostained for the dendritic marker MAP2 (red in
D and G) at DIV11. Green neurons are shRNA1-6 or Ctrl
transfected neurons (green in D and G). The scale bars
represent 20 μm. (H) Sholl analysis for dendritic complexity
of neurons transfected with control vector (Ctrl, n = 75) and
Dync1i1 shRNA1-6 (n = 101). In control neurons, the
maximum length of dendrite branches is found between
300 and 400 µm from the cell body. The shRNA1-6
transfected neurons show marked shortened dendrites
such that the majority of dendrites were located within 200
µm of the soma. Data are represented as mean ± SEM.
(I) Scatterplots with boxplots show that knockdown of
DYNC1I1 expression causes dendritic atrophy. Primary
hippocampal neurons are transfected with control vector
(Ctrl, n = 26, gray box), control shRNA (shRNA1-4, n = 26,
blue box) or shRNA1-6 (n = 26, red box) of Dync1i1 at
DIV6. Following transfection, neurons are cultured addi-
tional 1, 3 or 5 days before imaging and quantiﬁcation of
total dendritic length. The total dendritic lengths of control
neurons slightly increase with increasing days in vitro.
There is almost no length change of shRNA1-4 transfected
neurons. However, the total dendritic lengths of shRNA1-6
transfected neurons are gradually and dramatically
reduced at 3 and 5 days after transfection. *, P < 0.001.
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BRAF protects against dendritic atrophy caused
by DYNC1I1 knockdown in primary hippocampal
neurons
For signaling pathways, we focus on the RAS-RAF-MEK-
ERK mitogen activated protein kinase (MAPK) cascade and
phosphoinositide 3-kinase (PI3K)-Protein kinase B (PKB,
also known as AKT) pathways since they are both down-
stream signaling of neurotrophic factors (Chao, 2003). We
overexpress AKT or BRAF in rat primary hippocampal neu-
rons, where BRAF is the dominant functional RAF homolog
in MAPK cascade and brain among three mammalian RAF
proteins (ARAF, BRAF, and CRAF) (Galabova-Kovacs et al.,
2006; Zhong et al., 2007). Consistent with the role in the
signaling of neurotrophic factors, we have found that both
BRAF and AKT overexpression can promote dendritic
growth in control neurons (Fig. 2). The total dendritic lengths
(in μm, mean ± SD) of control (Fig. 2A) and BRAF overex-
pressed neurons (Fig. 2B) are 1007 ± 342 and 1491 ± 540,
respectively (Fig. 2F, gray and green boxes, P < 0.001,
t test), and the lengths of control (Fig. 2G) and AKT over-
expressed neurons (Fig. 2H) are 1021 ± 323 and 1581 ±
567, respectively (Fig. 2L, gray and green boxes, P < 0.001,
t test).
However, only BRAF can partially rescue dendritic com-
plexity and protect against dendritic atrophy caused by
DYNC1I1 knockdown (Fig. 2D–F), and the total dendritic
lengths (in μm, mean ± SD) of DYNC1I1-knockdown neu-
rons without (Fig. 2C) or with BRAF overexpression (Fig. 2D)
are 264 ± 135 and 776 ± 607, respectively (Fig. 2F, red and
purple boxes, P < 0.001, t test). Meanwhile, AKT overex-
pression has no effect on dendritic complexity and atrophy
(Fig. 2J–L), and the total dendritic lengths (in μm, mean ±
SD) of DYNC1I1-knockdown neurons without (Fig. 2I) or with
AKT overexpression (Fig. 2J) are 330 ± 197 and 347 ± 242,
respectively (Fig. 2L, P = 0.78, t test). Thus, the results
suggest that RAF signaling may have important role in pro-
tecting against neuronal atrophy caused dynein malfunction.
RAS-RAF-MEK signaling protects against dendritic
atrophy by activating MEK-dependent autophagy
To determine the signaling pathway for protecting dendritic
atrophy, we use H-RAS mutants that activate RAF-MEK or/
and PI3K-AKT signaling selectively or non-selectively. Domi-
nant active mutant RAS-G12V activates both RAF-MEK and
PI3K-AKT signaling, while RAS-G12V-T35S mutant selec-
tively activates RAF-MEK and the RAS-G12V-Y40C mutant
selectively stimulates PI3K-AKT (Fiordalisi et al., 2001). In line
with the above results of BRAF and AKT (Fig. 2), we have
found that RAS-G12V-T35Smutant but not RAS-G12V-Y40C
mutant has similar protective effect of BRAF on dendritic
atrophy caused by DYNC1I1 knockdown (Fig. 3A–E). The
total dendritic lengths (in μm, mean ± SD) of control (Fig. 3A),
shRNA1-6 (Fig. 3B), RAS-G12V-T35S (Fig. 3C), and RAS-
G12V-Y40C (Fig. 3D) transfectedneuronsare1188±228, 377
± 148, 623 ± 309, and 351 ± 234, respectively (Fig. 3E).
Compared to the length of shRNA1-6 group, the lengths of
RAS-G12V-T35S group are improved (P < 0.01, t test); RAS-
G12V also plays protective role in dendritic atrophy by
DYNC1I1 knockdown (562 ± 97 μm, mean ± SD, P < 0.01,
t test), while RAS-G12V-Y40C has no effect (P = 0.64, t test).
These results suggest RAS-RAF pathway rather than PI3K-
AKT signaling can play protective role in neuronal atrophy
caused by motor protein malfunction.
To conﬁrm the role of RAS-RAF signaling in neuronal
atrophy, we inhibit RAS-RAF-MEK signaling with pharmaco-
logical inhibitor trametinib, a speciﬁc inhibitor of MEK kinase
(Yamaguchi et al., 2011). As shown inFig. 3F–H,100nmol/L of
trametinib blocks the protective effect of BRAF in dendritic
atrophy induced by DYNC1I1 knockdown (P < 0.001, t test).
ForDYNC1I1-knockdownneuronsatDIV11, the total dendritic
lengths (μm, mean ± SD) of BRAF overexpressed neurons
without (Fig. 3F) or with 100 nmol/L of trametinib treatment
(Fig. 3G) are 740 ± 265 and 234 ± 112, respectively (Fig. 3H,
purple and blue boxes), where the length of trametinib treated
neurons with BRAF overexpression does not differ from the
length of shRNA1-6 transfected neurons (224 ± 102μm,mean
cFigure 2. BRAF but not AKT overexpression protects
against dendritic atrophy caused by DYNC1I1 deﬁ-
ciency in primary hippocampal neurons. (A–D) BRAF
overexpression protects against dendritic atrophy caused
by DYNC1I1 knockdown. Representative neurons are
transfected with control vector (Ctrl) or shRNA1-6 co-
transfected with or without BRAF at DIV6, and sequentially
imaged at DIV11. The scale bars represent 20 μm.
(E) Sholl analysis for dendritic complexity of neurons
transfected with control vector combined without (Ctrl, n =
37, black) or with BRAF (Ctrl + BRAF, n = 48, green) or
Dync1i1 shRNA1-6 combined without (n = 60, red) or with
BRAF (shRNA-6 + BRAF, n = 74, purple). Data are
represented as mean ± SEM. (F) Scatterplots with
boxplots show that BRAF overexpression promotes the
dendritic growth of Ctrl neurons and protects dendritic
atrophy caused by DYNC1I1 knockdown with shRNA1-6.
(G–J) AKT overexpression has no effect on dendritic
atrophy caused by DYNC1I1 knockdown. Representative
neurons are transfected with control vector (Ctrl) or
shRNA1-6 co-transfected with or without AKT at DIV6,
and imaged at DIV11. The scale bars represent 20 μm.
(K) Sholl analysis for dendritic complexity of neurons
transfected with control vector combined without (Ctrl, n =
26, black) or with AKT (Ctrl + AKT, n = 28, green) or
Dync1i1 shRNA1-6 combined without (n = 28, red) or with
AKT (shRNA-6 + AKT, n = 33, purple). Data are
represented as mean ± SEM. (L) Scatterplots with boxplots
show that AKT overexpression can also enhance the
dendritic growth of Ctrl neurons, but fail to protect from
dendritic atrophy caused by Dync1i1 knockdown with
shRNA1-6. *, P < 0.001.
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± SD, P = 0.67, t test). Meanwhile, 100 nmol/L of trametinib
slightly reduces the total dendritic lengths of control neurons
(Fig. 3H, gray and green boxes), where the lengths (in μm,
mean ± SD) of neurons treated with or without trametinib are
1016 ± 268 and 1220 ± 355, respectively (P < 0.01, t test).
Together, these results indicate that RAS-RAF-MEK signaling
can play protective a role in dendritic atrophy caused by
dynein malfunction.
BRAF protects against DYNC1I1 deﬁciency induced
dendritic atrophy by activating MEK-dependent
autophagy
Since dynein is required for autophagic clearance (Maday
et al., 2012; Kimura et al., 2008; Ravikumar et al., 2005),
dynein malfunction may cause protein aggregation and
mitochondrial dysfunctions, and result in neuronal atrophy.
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Figure 3. RAS-RAF-MEK signaling pathway protects against dendritic atrophy caused by DYNC1I1 deﬁciency. (A–D)
Dominant active mutant G12V of RAS and selective RAF-activator mutant (G12V, T35S) of RAS protect against dendritic atrophy
caused by DYNC1I1 knockdown, while selective AKT-activator mutant (G12V, Y40C) of RAS has no effect. Primary hippocampal
neurons are transfected with control vector (Ctrl) or shRNA1-6 co-transfected with RAS-G12V, RAS-G12V-T35S or RAS-G12V-Y40C
at DIV6, and imaged at DIV11. The scale bars represent 20 μm. (E) Scatterplots with boxplots show the total dendritic length
distribution of neurons transfected with control vector (Ctrl, n = 18, gray), shRNA1-6 (n = 25, red), shRNA1-6 with RAS-G12V (n = 7,
light blue), RAS-G12V-T35S (RAS-T35S, n = 25, green) or RAS-G12V-Y40C (RAS-Y40C, n = 25, purple). (F and G) Trametinib, a
speciﬁc inhibitor of MEK kinase in RAS-RAF-MEK signaling, inhibits the protective role of BRAF in dendritic atrophy caused by
DYNC1I1 deﬁciency with shRNA1-6. Neurons are co-transfected with BRAF and shRNA1-6 at DIV6, and imaged at DIV11. The scale
bars represent 20 μm. (H) Scatterplots with boxplots show the total dendritic length distribution of neurons transfected with control
vector treated without (n = 69, gray) or with 100 nmol/L of trametinib (n = 40, green), shRNA1-6 (n = 50, red), shRNA1-6 co-
transfected with BRAF treated without (n = 50, purple) or with 100 nmol/L of trametinib (n = 50, blue). *, P < 0.001.
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Thus, we have checked whether RAS-RAF-MEK signaling
can enhance autophagic function against atrophy in neuron.
Indeed, the number of autophagosomes labeled with GFP-
LC3 is dramatically increased in DYNC1I1-knockdown neu-
rons with BRAF overexpression (32 ± 19, Fig. 4C and 4E),
which is blocked by MEK inhibitor trametinib (9 ± 14, P <
0.001, t test, Fig. 4D and 4E). Whereas, the numbers of
autophagosomes in control neurons treated without (Fig. 4A)
or with trametinib, and DYNC1I1-knockdown neurons
(Fig. 4B) are 7 ± 6, 5 ± 5, and 6 ± 5, respectively (P = 0.25,
one-way ANOVA test, Fig. 4E). These results suggest BRAF
can activate MEK-dependent autophagy (Fig. 4C), which is
necessary for the protective role of BRAF in DYNC1I1 deﬁ-
ciency caused neuronal atrophy (Fig. 3F–H). Moreover, the
decreased number of autophagosomes in the presence of
MEK inhibitor trametinib indicates that BRAF increases
MEK-dependent autophagic inﬂux and activity.
Additionally, to test whether the activity of increased
autophagosomes is necessary for BRAF to play protective
role in neuronal atrophy, we used lysosomal protease inhi-
bitors (E64D and pepstatin A) to block autophagic clearance
(Klionsky et al., 2012). As shown in Fig. 4F–J, blocking
autophagic clearance inhibits the protective role of BRAF in
neuronal atrophy. Again, BRAF shows robust role of pro-
tection in dendritic atrophy caused by DYNC1I1 knockdown.
The total dendritic lengths (in μm, mean ± SD) of DYNC1I1-
knockdown neurons with or without BRAF overexpression
are 910 ± 322 and 233 ± 101, respectively (Fig. 4F–J). The
protective role of BRAF in neuronal atrophy is blocked by 1
μmol/L of E64D and pepstatin A treatment after transfection
(218 ± 135 μm, mean ± SD, P < 0.001 compared to BRAF
protected neurons, P = 0.62 compared to shRNA1-6 trans-
fected neurons, t test, Fig. 4I and 4J). Thus, the results
demonstrate that the activity of increased autophagosomes
is necessary for the protective role of BRAF in neuronal
atrophy. 1 μmol/L of inhibitors alone (E64D and pepstatin A)
slightly reduces the total dendritic lengths of control neurons
(Fig. 4J, green boxes), where the lengths (in μm, mean ± SD)
of neurons treated with or without inhibitors are 1097 ± 312
and 1314 ± 317, respectively (P = 0.01, t test, Fig. 4J). The
protective role of enhancing autophagic activity is also
demonstrated with mTOR inhibitor rapamycin (Fig. S2),
which also increase the number of autophagosomes in
neurons (Fig. S3).
Lysosomal inhibitors can also increase the number of
autophagosomes by blocking the function of lysosomal
protease (Fig. S3F and S3G), but result in slightly reduced
dendritic lengths (Fig. 4J). In addition, lysosomal inhibitors
can slightly but not signiﬁcantly increase the number of
autophagosomes in BRAF protected shRNA1-6 transfected
neurons (Fig. S3G), and block the protective role of BRAF in
neuronal atrophy, which supports that lysosomal inhibitors
block the activity of lysosomal enzymes to increase the
number of autophagosomes in neurons. Whereas, BRAF
increases the number of autophagosomes (Fig. 4C and 4E),
enhances the activity of autophagy, and protects neuronal
atrophy (Figs. 2D, 3F, and 4F), which are both MEK
dependent and blocked by MEK inhibitor trametinib (Figs. 4D
and 3G). Together, we reveal the protective function of RAS-
RAF signaling in neuronal atrophy is mediated by activating
MEK-dependent autophagy, which is protective and helpful
against neuronal atrophy by cleaning protein aggregations
and dysfunctional organelles, such as mitochondria.
BRAF also protects against dendritic atrophy caused
by mitochondrial dysfunction in primary hippocampal
neurons
Considering dynein is the major motor protein for cargo
transport in dendrites (Kapitein et al., 2010), especially for
mitochondrial transport, we have checked the motility of
dendritic mitochondria (Fig. 5A–C). As shown in the kymo-
graph of Fig. 5A (See also supplemental video 1), dendritic
mitochondria show active motility in control neuron, while
only a few dendritic mitochondria are motile in DYNC1I1-
knockdown neuron (Fig. 5B and supplemental video 2). To
quantify the motility of dendritic mitochondria, motile and
stationary dendritic mitochondria are separated with fast
Fourier transform (FFT) algorithm (Fig. 5A and 5B). Con-
sidering motile mitochondria is prone to be ambiguous and
overestimated due to the vague deﬁnition of motile mito-
chondria and the effect of photobleaching, we have quanti-
ﬁed and compared the absolutely stationary mitochondria
(The third row in Fig. 5A and 5B). The results demonstrate
that stationary pool of dendritic mitochondria (75% ± 6%,
mean ± SD in percentage) in DYNC1I1-knockdown neurons
is signiﬁcantly increased (versus 68% ± 9% in control neu-
rons, P < 0.001, t test, Fig. 5A–C).
Illustrated in Fig. 5A–C, DYNC1I1 knockdown decreases
mitochondrial motility, which may result in accumulation of
dysfunctional mitochondria (Maday et al., 2012; Xie et al.,
2015). In turn, the accumulation of dysfunctional mitochon-
dria might be an important or major factor to cause neuronal
atrophy. To inspect this, we used a speciﬁc inhibitor (tetram-
ethylrhodamine ethyl ester, TMRE) of mitochondrial function
(Scaduto and Grotyohann, 1999), which is a frequently used
mitochondrial marker. As shown in Fig. 5D–J, compared to
the total dendritic lengths (in μm, mean ± SD) of control
neurons treated with relevant DMSO solution (944 ± 278,
Fig. 5D and 5H) or a non-inhibitory mitochondrial marker
(tetramethylrhodamine methyl ester, TMRM) at 50 nmol/L
(Scaduto and Grotyohann 1999) (818 ± 234, Fig. 5H, blue
box), neurons treated with 50 nmol/L of TMRE show short-
ened dendritic lengths (421 ± 229, P < 0.001, t test, Fig. 5E
and 5H, red box). Thus, mitochondrial dysfunction is sufﬁcient
to result in neuronal atrophy.
Moreover, since both dynein and mitochondria are ther-
apeutic targets in neurodegeneration (Eschbach and
Dupuis, 2011; Banks and Fisher, 2008; Moreira et al., 2010),
we are also wondering whether BRAF can protect against
dendritic atrophy induced by mitochondrial dysfunction. For
the total dendritic lengths (in μm, mean ± SD) of BRAF
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Figure 4. BRAF overexpression protects against DYNC1I1 deﬁciency induced dendritic atrophy by activating MEK-
dependent autophagy. (A–D) BRAF overexpression enhances protective autophagy, which is MEK dependent. Primary
hippocampal neurons are co-transfected GFP-LC3 with blank vector, shRNA1-6, shRNA1-6 and BRAF treated without or with 100
nmol/L of MEK inhibitor trametinib at DIV6, cultured additional 5 days and imaged at DIV11. Autophagosomes (green puncta) are
labeled with GFP-LC3. All photos of GFP-LC3 are imaged with confocal microscope and further deconvolved for clarity. The scale
bars represent 2 μm. (E) Scatterplots with boxplots show the number distribution of GFP-LC3 puncta in the soma of neurons
transfected with control vector treated without (n = 41) or with 10 nmol/L of trametinib (n = 22), shRNA1-6 (n = 48), shRNA1-6 co-
transfected with BRAF treated without (n = 39) or with 100 nmol/L of trametinib (n = 44). (F–I) Lysosomal protease inhibitors (E64D
and pepstatin A) can inhibit the protective role of BRAF in dendritic atrophy caused by DYNC1I1 knockdown with shRNA1-6. Neurons
are transfected and treated without or with 1 μmol/L of E64D and pepstatin A at DIV6, cultured additional 5 days and imaged at DIV11.
The scale bars represent 20 μm. (J) Scatterplots with boxplots show the total dendritic length distribution of neurons transfected with
control vector treated without (n = 29, gray) or with 1 μmol/L of E64D and pepstatin A (n = 30, green), shRNA1-6 (n = 30, red),
shRNA1-6 co-transfected with BRAF treated without (n = 30, purple) or with 1 μmol/L of E64D and pepstatin A (n = 30, blue). *, P <
0.001.
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Figure 5. BRAF overexpression also protects against dendritic atrophy caused by mitochondrial dysfunction in primary
hippocampal neurons. (A and B) Dync1i1 Knockdown decreases dendritic mitochondrial motility in primary hippocampal neurons. For
clarity andquantiﬁcation,motileandstationarydendriticmitochondriaareseparatedwith fastFourier transform(FFT)algorithm.Kymographs
show active mitochondrial motility in control neuron (A, Ctrl) and a few motile dendritic mitochondria in DYNC1I1-knockdown neuron (B,
shRNA1-6). In kymographs, vertical lines represent stationarymitochondria, and slant lines or curves indicatemotilemitochondria. Neurons
are co-transfected at DIV6 with DsRed-mito and control vector (A) or shRNA1-6 (B), imaged at DIV11 and sequentially analyzed. The scale
bars represent 10μm(xaxis) and100seconds (yaxis). (C)Scatterplotswith boxplots show thepercentagedistributionof stationary dendritic
mitochondria in neurons transfected with control vector (n = 32) or shRNA1-6 (n = 32). (D–G) BRAF overexpression also protects against
dendritic atrophycausedbymitochondrial dysfunction.Neuronsare transfectedwithcontrol vector (Ctrl) orBRAF treatedwith control solution
or with 50 nmol/L of speciﬁcmitochondrial function inhibitor TMRE at DIV6, cultured additional 5 days and imaged at DIV11. The scale bars
represent 20 μm. (H) Scatterplots with boxplots show the total dendritic length distribution of neurons transfected with control vector treated
with vehicle (Ctrl, n = 53, gray), with 50 nmol/L of TMRM (n = 31, blue) or 50 nmol/L of TMRE (n = 63, red), or transfected with BRAF treated
without (n = 24, green) or with 50 nmol/L of TMRE (n = 32, purple). *, P < 0.001.
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overexpressed neurons, BRAF promotes the dendritic
growth of non-treated neurons (1570 ± 229, Fig. 5F and 5H),
similar as shown in Fig. 2B and 2F; BRAF overexpressed
neurons are somewhat resistant to TMRE treatment, and
protect dendrites from atrophy induced by functional inhibi-
tion of mitochondria (775 ± 607, Fig. 5G and 5H, purple box).
The total dendritic lengths of BRAF overexpressed neurons
are signiﬁcantly improved (P < 0.001, t test) compared to the
lengths of TMRE treated control neurons (Fig. 5H red box).
Together, these results based on above cellular models
indicate that BRAF has a general protective role in neuronal
atrophy caused by dynein malfunction or mitochondrial
impairment.
DISCUSSION
Dynein is not only the major motor protein for dendritic cargo
transport (Kapitein et al., 2010) and dendritic mitochondrial
motility (Fig. 5), but also plays important roles in axonal
structures and polarities (Song et al., 2009; Zheng et al.,
2008). DYNC1I1 knockdown causes abnormal ER distribu-
tion in axon (Fig. S4), which is in line with the reported
gatekeeper function of dynein (Song et al., 2009; Zheng
et al., 2008). As an important cargo binding subunit of dynein
(Ha et al., 2008), dynein intermediate chains (DYNC1I1 and
DYNC1I2) are necessary for the functional integrity of dynein
(Figs. 5 and S4) and the maintenance of neuronal architec-
ture (Fig. 1). In addition, functions of both DYNC1I1 and
DYNC1I2 are regulated by phosphorylation. The phospho-
rylation of DYNC1I1 serine 83 or DYNC1I2 serine 84 inhibits
dynein intermediate chain binding to dynactin or paxillin
(Vaughan et al., 2001; Rosse et al., 2012); while the phos-
phorylation of DYNC1I1 serine 80 or DYNC1I2 serine 81 is
MAP kinase ERK1/2 dependent and can strengthen dynein
activity in signaling cargos transport (Mitchell et al., 2012). In
our study, we cannot exclude that the protective role of RAS-
RAF-MEK signaling in neuronal atrophy may be partially due
to upregulating the phosphorylation of DYNC1I2 serine 81
and thus partially compensate the dynein malfunction by
DYNC1I1 knockdown, although we fail to detect any change
of phosphorylation of DYNC1I2 serine 81 for control and
DYNC1I1 knockdown (data not shown) in primary cultured
hippocampal neuron, which may be explained by the low
transfection efﬁciency of primary neuron and the expression
of DYNC1I2C in glia.
Protective role of RAS-RAF-MEK axis in neuronal
atrophy caused by dynein malfunction
In corroboration with our results, transgenic activation of
RAS in neurons promotes neuronal growth and protects from
lesion-induced degeneration (Heumann et al., 2000), but the
mechanism is unknown; in addition, selective activation of
BRAF can provide neuroprotection both in vitro and in vivo
although it is not MEK dependent (Chin et al., 2004). Here,
we identify that RAS-RAF signaling protects neurons against
dendritic atrophy arisen from dynein malfunction, which
relies on MEK-dependent autophagy (Fig. 4). MEK-depen-
dent autophagy can be either protective or destructive
autophagy (Wang et al., 2009) in non-neuronal cells. The
role of MEK-dependent autophagy in neuron is unknown yet.
Trametinib treatment and BRAF in control neurons doesn’t
affect the numbers of autophagosomes (Figs. 4 and
Fig. S3E), which suggests that MEK-dependent autophagy
has minor role in neuron under normal condition. However,
we demonstrate that RAS-RAF pathway activates protective
autophagy in primary hippocampal neuron with DYNC1I1
knockdown (Fig. 4), which is favorable for structural and
functional integrity of neuron.
Both RAS-RAF and PI3K-AKT pathways are necessary
for dendritic morphogenesis (Kumar et al., 2005) and neuron
survival (Mazzoni et al. 1999). Additionally, PI3K-AKT sig-
naling has a major role in antiapoptotic function (Brunet
et al., 2001). Here, we demonstrate that only RAS-RAF-MEK
pathway has the protective role in dendritic atrophy cause by
DYNC1I1 knockdown (Fig. 6). Interestingly, it is recently
reported that inhibition of RAS-MAPK pathway has a role in
longevity of Drosophila (Slack et al., 2015). However, to
avoid compromising brain function of higher animals (Fig. 2–
4), our results raise caution about inhibiting RAS-RAF-MEK
signaling for longevity. Thus, it deserves further studies on
the roles of RAS-RAF-MEK signaling in longevity and neu-
ronal atrophy with models of higher animals, such as rodents
or monkeys.
A more general role of RAS-RAF-MEK signaling
in neuronal atrophy
In the past decades, dominated researches and drug
developments have focused or based on cholinergic















Figure 6. Schematic summary of general roles of RAS-RAF-
MEK pathway in protecting dendritic atrophy caused by
dynein malfunction or mitochondrial dysfunction.
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Alzheimer’s disease (Becker et al., 2008; Craig et al., 2011;
Karran et al., 2011). However, the continual failures of clinical
trials for neurodegenerative disorders suggest that it is
important and necessary to think about new models and
strategies, such as motor protein dynein malfunction and
mitochondrial dysfunction, both of which are in the spotlight
of neurodegeneration therapy, ALS in particular (Eschbach
and Dupuis, 2011; Banks and Fisher, 2008; Moreira et al.,
2010; Payne and Chinnery, 2015).
Here, based on the cellular models of neuronal atrophy,
we demonstrate that BRAF has a general protective role in
neuronal atrophy caused by dynein malfunction or mito-
chondrial impairment (Fig. 6). Dynein malfunction by
DYNC1I1 knockdown decreases mitochondrial motility
(Fig. 4), which may augment mitochondrial pathology. This
study provides some missing linkages among dynein, mito-
chondria, and atrophy/degeneration. These ﬁndings about
the RAS-RAF-MEK pathway for neuronal atrophy protection
provide a therapeutic intervention signaling against the on-
sets of neuronal atrophy caused by dynein malfunction or
mitochondrial impairment. Importantly, neuronal atrophy is
not only the hallmark of neurodegeneration, such as ALS,
but also a continuous process in adult brain with increasing
age (Pakkenberg et al., 2003; Fox and Schott, 2004).
Therefore, more speculatively, it might even imply a potential
target to ameliorate memory decline due to age-related brain
atrophy.
MATERIALS AND METHODS
Additional information can be found in the supplemental materials
and methods.
Plasmids and shRNA
The isoforms of Dync1i1 are cloned into the vector pEGFP-N1 with
restriction sites EcoRI and BamHI (NEB). The shRNA1-6 oligonu-
cleotide for Dync1i1 (5′-GCATGGAGCTGGTGTACAA-3′) and con-
trol shRNA1-4 oligonucleotide (5′-GCTGGAGCCAACCTTTCTT-3′)
are constructed into the modiﬁed pSUPER vector (Kanr, EGFP
expression) with BglII and HindIII restriction sites. The calcium
phosphate method is used for transfection.
Data and statistical analysis
Imaging is performed using an Olympus FV1000 confocal micro-
scope with a 40×/0.95 objective (Olympus) for dendritic length
imaging and a 60×/1.2w objective (Olympus) for high-resolution
imaging at room temperature or mitochondrial motility study at 37°C.
The sholl analysis of neuritic morphology and complexity is per-
formed using Fiji/ImageJ software with Simple Neurite Tracer. Pho-
tos of GFP-LC3 labeled autophagosomes are imaged with confocal
microscope and further deconvolved using the SharpStack Total
Deconvolution function of Image-Pro Plus (Media Cybernetics). The
numbers of autophagosomes are counted by triple-blinded analysis.
Data sets in sholl-analysis graphs are presented as mean ± SEM
from repeats in at least three independent experiments, while data
sets in text are presented as mean ± SD. Scatterplots with boxplots
are plotted with R software. For mitochondrial motility study, motile
and stationary dendritic mitochondria are separated with an immo-
bile ﬁlter, which is computed with FFT algorithm. When comparing
multiple samples in a group, one-way ANOVA test is used. When
comparing two samples, two-tailed Student’s t test is used.
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